ArticleRenal failure2026
Sex-specific association between metabolic score for insulin resistance and mortality in incident peritoneal dialysis patients.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relationship between metabolic score for insulin resistance index (METS-IR) and all-cause and cardiovascular disease (CVD) mortality in peritoneal dialysis (PD) patients remains unexplored. Hence, we aimed to assess the association of METS-IR with mortality, specifically examining sex differences.
methodsIn this multicenter cohort study, a total of 3,471 patients were enrolled between 01 January 2006 and 31 December 2017. Associations between METS-IR and all-cause and CVD mortality were examined using multivariate Cox regression analysis, with sex-based differences also assessed.
resultsParticipants had a mean age of 51.34 ± 14.61 years, 44.04% female. The mean MESTS-IR in Quartile 1, Quartile 2, Quartile 3, and Quartile 4 was 26.22 ± 2.18, 31.40 ± 1.21, 35.94 ± 1.42 and 44.07 ± 5.29 respectively. A comparison of Quartile 4 to Quartile 1 using the multivariate Cox regression analysis revealed significant increases in the hazard ratio (HR) for all-cause mortality (HR: 1.42, 95% confidence interval (CI): 1.02 to 1.97) and CVD mortality (HR: 1.78, 95% CI: 1.16 to 2.54) in the entire population. In female PD patients, the Quartile 4 was associated with an approximately 126% greater risk of all-cause mortality and 165% greater risk of CVD mortality compared with Quartile 1 in the multivariate analysis. However, the result showed no significance in men.
conclusionsThe METS-IR could serve as an effective prognostic indicator of mortality in women undergoing PD, indicating that early detection and intervention toward insulin resistance, represented by the METS-IR index, may offer clinical benefits for this identified group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.